Xenex Announces StrikeForce Disinfection Service

LightStrike Robot Destroys COVID-19 Virus in 2 Minutes

June 22, 2020

Xenex notes as cities across Texas report a spike in the number of coronavirus cases, businesses and organizations are looking for strategies to combat the virus within their facilities.

Xenex Disinfection Services, the world leader in UV disinfection for healthcare facilities, today announced the launch of StrikeForce, an innovative disinfection service. For the first time, organizations can engage Xenex’s team of environmental disinfection experts on a project basis to utilize Xenex LightStrike Germ-Zapping Robots to kill harmful viruses, bacteria and spores that linger on commonly touched surfaces and pose a risk for disease transmission. StrikeForce is currently limited to engagements in Texas.

“The entire world is thinking about disease transmission as a result of the COVID-19 pandemic. We had numerous requests from businesses who wanted us to bring robots in and disinfect their facilities for them to help ensure that their environment was virus-free. In response to market demand, we developed the StrikeForce service to enable companies to provide their staff and clients peace of mind through innovative disinfection solutions with minimal downtime,” said Irene Hahn, vice president of sales for Xenex.

The LightStrike disinfection robot is proven to destroy Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in two minutes. Surfaces contaminated with COVID-19 pose a grave threat to the safety of healthcare workers, patients, frontline responders, military service members, cruise line passengers, hotel guests and citizens everywhere. Deactivating the COVID-19 virus on surfaces is a critical and necessary step to providing a safe environment as businesses reopen and people get back to work. Restaurants, car dealerships, hotels, office buildings, gyms, and many other spaces can benefit immediately from StrikeForce disinfection as the global pandemic demonstrates the need for quick and effective disinfection wherever people work, play, or live.

LightStrike Germ-Zapping Robots use a xenon lamp to generate bursts of high intensity, broad spectrum (200-315nm) ultraviolet (UV) light that’s more intense than sunlight. Different pathogens are susceptible to UVC light at different wavelengths. With broad spectrum germicidal light, Xenex LightStrike robots quickly deactivate viruses, bacteria and spores where they are most vulnerable without damaging materials or equipment.

Xenex is the world leader in UV disinfection for healthcare facilities and its LightStrike robots have been deployed in more than 500 healthcare facilities around the world, including HonorHealth, the Mayo Clinic, MD Anderson Cancer Center, Stanford, and USC. The robots work quickly and do not require warm-up or cool-down time, so facilities are able to disinfect dozens of rooms per day (per robot). Hospitals have published peer-reviewed studies showing significant reductions in Clostridium difficile (C.diff), MRSA, VRE and/or Surgical Site Infection (SSI) rates after integrating Xenex’s infection prevention programs and using LightStrike robots to supplement their environmental disinfection efforts.

SourceXenex
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version